Reach Messaging Holdings, Inc. (RCMH.OB) Goes Public on OTCBB [View instapost]
RCMH.OB:Reach Messaging Holdings Inc.
Reach Messaging Holdings Inc. helps companies extend their brands through customized mobile applications and Bots used on instant messaging (IM) platforms. Since 2007, Reach Messaging has been in the Bot development business for America Online (seekingalpha.com/symbo...), which operates on the AOL Instant Messenger (seekingalpha.com/symbo...). The Company is transitioning to the mobile applications market and is currently developing a variety of apps for social media platforms including Facebook and all of the major mobile devices such as the iPhone, BlackBerry, Android and Digital Signage.
A leading developer of industry specific mobile phone application and specialized platform technology, today announced the Company will be launching a Physical Fitness App through which "CrossFit" athletes can communicate, challenge and compete with one another. The app will be available on the iPhone and Droid upon release, which the Company anticipates in the near future.
The mobile app itself will be a comprehensive tool designed specifically for the CrossFit athlete and include all the necessary tools for CrossFit such as a timer, list of CrossFit specific exercises to reference, Workout of the Day (seekingalpha.com/symbo...) tracker, and the ability to locate the nearest CrossFit Affiliate Gym. Additionally, the app will have a unique feature that allows CrossFit athletes all over the world to challenge other users, friends or random opponents to a specific workout. The user being challenged will be notified through push notification.
Reach Messaging Signs Deal With Mall Development Company to Use Its "Mall Buddy 2.0" Mobile App Throughout 12 Retail Mall Locations Company's First Multi-Mall Deal is With the Largest Privately Owned Shopping Center Development and Management Company in the US.
Reach Messaging's "Mall Buddy 2.0" Platform is a free mobile app that consumers can download and use when shopping at participating retail malls. The app includes features such as "Reward Zone" gift card integration as well as other coupons and specials offered by stores in and around the mall, friend finder to locate other users in the area, one touch access to mall security and directions the mall. As outlined in the agreement, Reach Messaging will get a percentage of revenue generated by advertising sales to retail stores in and around the malls.
Per Equity @ .00478 / Share; Current Market Cap 4M; [Paid In Equity 4.835M], 840M Shares O/S.
Sum Trading At: ,Primary Metric per Equity: ($0.244208) M, 406.3 ,Metric Weighted per Price Range / Change, 6.301_404 ,Combined Weight Adj Trade Metric, 593.740 ,for -($1.044)M Market Cap, for, (0.001244) off adjusted level price of .006024;
Estimate of Forward Activity:
Equity $$MM: (0.244208) MinRetGrowth: 0.03 MinRetInv: 0.05 Weighted Cost of Capital: 78.5% Estimated Local Continuing Value in $$M: (0.132502) Estimated Factor NOT LOCAL in $$M: 9.412007 Estimated ContinuingValue :In Line With Avg Oper Loss Annualized MRQ $M: '10 & '11: (1.247,113) Est NOT LOCAL Price / 1.07M Market Cap : 0.001274_24_22 (0.0015), ,Factor Forward. (0.858), ,Not Local Price To.
24. Other Inc or Loss 0.00 ,M, 10-Q 0.32 , 0.00 , 1.0313 , 0 ,July 2011, 0.33
Sum Trading At: ,Primary Metric per Equity: ($4.428) M, 693,356 ,Metric Weighted per Price Range / Change, 4.73_404 ,Combined Weight Adj Trade Metric, 703,966.1_15_8_86_404 ,for +$0.553M Market Cap, for, 0.017 on adjusted level price of .303;
Estimate of Forward Activity:
Equity $$MM: (4.428) MinRetGrowth: 0.03 MinRetInv: 0.05 Weighted Cost of Capital: 92.47% Estimated Local Continuing Value in $$M: (1.992072) Estimated Factor NOT LOCAL in $$M: 4.824,522M Estimated ContinuingValue :In Line With R&D Expense Annualized MRQ / Net Loss ttm$$M: (9.610,792) Est NOT LOCAL Price / 5.24M Market Cap : 0.16_12_22 (0.2959) ,Factor Forward. (0.54494) ,Not Local Price To.
Current Market Cap 10.72M; Off the high of $1.15_66_19
News / Recent Presentation's. NewCardio Selected to Present at Wells Fargo Securities Healthcare Conference.
NewCardio Selected to Present at 33rd Annual International Conference of the IEEE Engineering in Medicine and Biology Society.
NewCardio Selected to present @ the Cardiac Diagnostic Technology at MDB Capital's Bright Lights Conference in New York City.
NewCardio Selected to Present Latest QTinno Performance Improvements at FDA-Sponsored Conference on Cardiovascular Safety in Drug Development.
About NewCardio, Inc.
NewCardio is a cardiac diagnostic and services company developing and marketing proprietary software platform technologies to provide higher accuracy to, and increase the value of, the standard 12-Lead 3D ECG. NewCardio's 3D ECG technology software platform reduces the time and expense involved in assessing cardiac status while increasing the ability to diagnose clinically significant conditions which were previously difficult to detect. NewCardio's software products and services significantly improve the diagnosis and monitoring of cardiovascular disease, as well as cardiac safety assessment of drugs under development. For more information, visit newcardio.com.
Suspect Detection Systems Inc. (SDSS.OB) is “One to Watch” [View instapost]
SDSS: Suspect Detection Systems Inc.
Co. Statement: - Total revenues during the past two years have exceeded $4M; During the quarter, the company completed a major sale to a governmental agency, and it is believed that follow-up sales with the customer are likely in the future. In addition, the company has begun raising capital, which is intended to enable the company to grow significantly as it builds toward the fulfillment of its full business plan. The capital raise is expected to be completed in the coming months.
Per Equity @ 8.75 Cents; [Off the high of 11.2 Cents;], Gross Profit as % of Revenue MRQ 90%; Current Market Cap 6.507M; 2009:27 Cents;
Sum Trading At: ,Primary Metric per Equity: $1.357 M, 892 ,Metric Weighted per Price Range / Change, 4.63_4_38 ,Combined Weight Adj Trade Metric, 767.007 ,for +$0.5M Market Cap, for, 0.006398 on .081102 / Share;
Estimate of Forward Activity:
Equity $$MM: 1.357 MinRetGrowth: 0.03 MinRetInv: 0.05 Weighted Cost of Capital: 139.622% Estimated Local Continuing Value in $$M: 0.399722M Estimated Factor NOT LOCAL in $$M: 16.212047M Estimated ContinuingValue :In Line With Sales Annualized 2011, MRQ: 6.480339M Est NOT LOCAL Price / 4.43M Market Cap : 0.0578 0.085 ,Factor Forward. 0.68_3 ,Not Local Price To.
Suspect Detection Systems Inc., through its subsidiary Suspect Detection Systems Ltd., is a developer of proprietary counter terrorism and crime prevention technology designed to identify threats in real-time, and prevent incidents before they are carried out. The technology platform detects the hidden "hostile intent" of assailants - before they commit their intended acts - with a high degree of accuracy. The system can also be used after a crime is committed to quickly identify criminals from among a general population pool, including suspects.
Learn more about Suspect Detection Systems and Cogito Technology at
Vicor Technologies (OTCBB: VCRT) - Breaking down the "PD2i(R) Studies" [View instapost]
VCRT: Vicor Technologies:
Current Market Cap; 7.06M;
@ 10 Cents; Per Equity; Accum Deficit (59.708M); Equity (8.428M); Development Stage Since 2000;
Desired Level / Sum Trading At: ,Primary Metric per Equity: ($8.428) M, 1000.013 ,Metric Weighted per Price Range / Change, 6.8_12_404 ,Combined Weight Adj Trade Metric, 1512.106 ,for -($1.7)M Market Cap, for, (0.04) off .14;
Estimate of Forward Activity:
Equity Deficit$$MM: (8) MinRetGrowth: 0.03 MinRetInv: 0.05 Weighted Cost of Capital: 85.904% Estimated Local Continuing Value in $$M: (4) Estimated Factor NOT LOCAL in $$M: 1.33 Estimated ContinuingValue : In Line with Development Stage Expenses Since 2000;: (5.436,551) Est NOT LOCAL Price / 4.048M Market Cap : 0.08606 (0.12) ,Factor Forward. (0.74) ,Not Local Price To.
Profile: Vicor is a medical diagnostics company focused on commercializing noninvasive diagnostic technology products based on its patented, proprietary point correlation dimension algorithm (the PD2i® Algorithm”). The PD2i®Algorithm facilitates the ability of physicians to accurately risk stratify a specific target population to predict future pathological events such as autonomic nervous system dysfunction, cardiac mortality (either from arrhythmic death or congestive heart failure) and imminent death from trauma. The Company believes that the PD2i® Algorithm represents a noninvasive monitoring technology that physicians and other members of the medical community can use as a new and accurate vital sign and is currently commercializing two proprietary diagnostic medical products which employ software utilizing the PD2i® Algorithm: the PD2i Analyzertm (sometimes also referred to as the PD2i Cardiac Analyzertm and the PD2i-VStm (Vital Sign). It is also anticipated that the PD2i®Algorithm applications will allow for the early detection of cerebral disorders as well as other disorders and diseases.
23. Common / Other, 0.0224 ,M, 10-Q 0.06 , 452 , 0.9 , 403 , July 2011, 0.05
24. Report a Fwd Net Loss (1.763_656) ,M, 10-Q 0.06 , (5.724664) , 0.9 , (5.343) , July 2011, 0.06
Sum Trading At: ,Primary Metric per Adjusted Equity: ($2.222,756) M, 445.86 ,Metric Weighted per Price Range / Change, 4.56 ,Combined Weight Adj Trade Metric, 397.404 ,for +$0.9M Market Cap, for, 0.005 on .055;
Description of Company; Viropro Inc., a public company, offers Contractual Research and Manufacturing Services to the biopharmaceutical industry through cell line and process development.
The Manufacturing Processes Developed Are Out-licensed to various international partners who produce and distribute the final product. The company is currently seeking partnerships for its biosimilar (aka follow-on biologics) cell lines and manufacturing processes.
Viropro uses patented cell lines and expression vectors that clearly out-perform the industry standards and allow partnering companies to obtain industrially competitive yields. Our technology is ideally suited for Monoclonal Antibody process development.
Viropro, Inc. conducts operations through its subsidiaries Viropro International Inc., Biologics Process Development, Inc. and Alpha Biologics Sdn. Bhd. Viropro specializes in the transfer of its technologies for industrial production of biopharmaceutical therapeutic proteins for the treatment of various diseases including cancer, diabetes, hepatitis and multiple sclerosis. The Company’s principal objective is to provide its high-yield manufacturing process technology to biopharmaceutical companies in global markets with unmet medical and/or market needs.
BPD, located in Poway, CA, has been providing contract laboratory services to the biotechnology and biopharmaceutical industries for more than decade. The range of services includes molecular biology, cell culture, fermentation, protein purification, frozen storage, contract manufacturing, process scale-up and consulting services. BPD has an impressive list of clients that range from university laboratories to well-known biotechnology and biopharmaceutical companies.
Intas Biopharmaceuticals Limited is a fully integrated biopharmaceutical company based out of Ahmedabad, Gujarat, India. Since launch of biotechnology operations in May 2000, Research & Development (R&D) and Manufacturing of Biopharmaceutical products with a special focus on Oncology (Cancer) are the major thrust areas for the company. Intas Biopharmaceuticals is India's first and only biopharmaceutical company to receive European Union -Good Manufacturing Practice (EU-GMP) certification for its manufacturing facility.
American Medical Alert Corp. Q4 2007 Earnings Call Transcript [View article]
MDHI; MEDICAL ALARM CONCEPTS.
MDHI, Medical Alarm Concepts, is similar to AMAC, Mentioned Above; There was no specific mention of MDHI on seekingalpha.com; and this is an outdated posting; Adequate area to post information on MDHI..... Similar Companies;
MDHI has some active interest in the company; There has been 3 Schedule 13D's filed recently; [General statement of acquisition of beneficial ownership];
Also, Filed to Report 10-Q Late; Company may be in the process of being purchased..... Finalizing Equity Schedules; etc;
Current Market Cap 475.3K; Last .0015 / Share;
Per Most Recent Quarterly Report, Per Equity @ .001275_404 / Share; 316.863M Shares O/S; Market Cap of 404K;
Sum Trading At: ,Primary Metric per Equity: ($2.049) M, 0.022504 ,Metric Weighted per Price Range / Change, 6.4_78_404 ,Combined Weight Adj Trade Metric, 0.03000375 ,for -($0.119_46)M Market Cap, for, (0.00038) off .00165;
Estimate of Forward Activity:
Equity Deficit$$MM: (2.049) MinRetGrowth: 0.03 MinRetInv: 0.05 Weighted Cost of Capital: 71.4% Estimated Local Continuing Value in $$M: (1.204_702) Estimated Factor NOT LOCAL in $$M: 1.000102 Estimated ContinuingValue : In Line with 6 Mos Loss Annualized: (1.204_823) Est NOT LOCAL Price : 0.0098 (0.004), ,Factor Forward. (2.58_16_6) ,Price To.
Profile: Medical Alarm Concepts™ currently offers a unique, patented medical emergency alarm system that is different from other personal emergency response (PERS) systems on the market today. MDHI's MediPendant™ product provides several revolutionary and highly desirable features, including the ability to speak and listen to the operator directly through the pendant, an extended range of up to approximately 600+ feet from the base station enabling the user to move virtually anywhere in or around their home, and a call center staffed around the clock with all EMT-certified operators, who are guaranteed to stay on the line with the MediPendant™ user until the problem is resolved or help arrives. MediPendant's™ advanced technology also allows for three-way calling between the operator, the user and the dispatched first responders and/or a friend and family member.
They have also recently acquired two US Patents; Both patents relate to existing and future technologies in the design and functionality of the medical alarm, a market that is growing at unprecedented rates. The re-issuance of these patents is a significant step toward ensuring the long-term success of the Company with regards to both its existing line of products as well as new products that are currently in design and/or development.
CTD Holdings, Inc. Manufacturing and marketing of Cyclodextrin-based compounds.
per Equity @ .063 / Share;
Sum Trading At: ,Primary Metric per Equity: $1.393 M, 630 ,Metric Weighted per Price Range / Change, 6.20 ,Combined Weight Adj Trade Metric, 903.622_404 ,for -($0.5)M Market Cap, for, (0.015) off .078
Estimate of Forward Activity:
Accum Deficit$$MM: (2.323) MinRetGrowth: 0.032 MinRetInv: 0.059 Weighted Cost of Capital: 158.813% Estimated Local Continuing Value in $$M: (0.7) Estimated Factor NOT LOCAL in $$M: 0.0174 Estimated ContinuingValue : Operating Loss / In Line With Recent Reports: (0.0119) Est NOT LOCAL Price : 0.06 (0.00033_4_13_8), ,Factor Forward. 2.3346, ,Not Local Price To Sales. Avg Sales 910,233K, and Increasing;
Telecommunications Systems: Calling Another 'Stunningly Cheap' Stock [View article]
TSYS: Just received 10-K for year ended 2010;
The balance sheet reports 216M of Equity; However if you deduct Cash, Goodwill, Deferred Tax Assets, add back Deferred Revenue, Non Current Deferred Tax Liab;
(7M);
Unbilled Receivables of 32M; which could be the government sector business that creates the revenue timing problem mentioned above;
Sales have increased considerably from 220M to 388M, '08, '09, '10;
R&D Exp from 16M to 30M; [Good to see that]
Stock based comp expense from 4M to 10M;[Good to See that as well]
So therefore; Mr Tos and his Anti-takeover provisions do not mean much when you are sitting on 80M in Cash; with the possibility of being paid an additional 300M; and whatever you received in other payments over the years;
[Note: Paid in Equity is 297.5M on Accum Deficit of 82.6M]
Estimate of Buyout Valuation:
Recent Net Income $$MM: 16 MinRetGrowth: 0.03 MinRetInv: 0.05 Weighted Cost of Capital: 360.722% Estimated Local Continuing Value in $$M: 1.365 / 1.4M Estimated Factor NOT LOCAL in $$M: 100.722 Estimated ContinuingValue: Gross Profit $$M: 138 Est NOT LOCAL Buyout Price : 5.33 / Share. Estimated Buyout Valuation: $302.26M - $304.64 2.43, ,Factor Forward / Gross Profit per Shares; 2.20, ,Price To per Buyout Price; 1.1104x / 1.12x to Current Market Cap;
Net Cash provided by operating activities has increased from 26M to 73.4M;
Disclosure: [X] Own Shares of TSYS. This is a comment / valuation estimate of a potential buyout based on recent 10-K Equity and Sales Disclosure; This is not meant to comment on a specific fund or funds that may own shares of TSYS in their portfolio; This is not meant to comment on Return Year To Date; [Gross Profit YE 2010: Approx 140M]
24. Common Stk Amt ,[35K], 10-Q, 0.0475 , 475 , 0.08 , 40 ,Price5, (0.004)
Sum Trading At: ,Primary Metric per SE: -($2.219) M, 508.605 ,Metric Weighted per Price Range / Change, 3 ,Combined Weight Adj Trade Metric, 54 ,for +$6.2M Market Cap, for, 0.0175 on adjusted level price of 3.00 Cents;
Estimate of Forward Activity:
Recent Net Loss $$MM: (0.428) MinRetGrowth: 0.03 MinRetInv: 0.05 Weighted Cost of Capital: 92.528% Estimated Local Continuing Value in $$M: (0.146328) Estimated Factor NOT LOCAL in $$M: 3.07 Estimated ContinuingValue: R&D Net Loss $$M: (0.449228) Est NOT LOCALPrice : 0.035 (0.001271), ,Factor Forward. (28) ,Price To.
Per Volume Last 5.48 DAYS, M of Shares: (319.121)M , (0.204636)M Market Cap; Sum Trading At: ,Primary Metric(s) per Volume: (0.21) ,Metric Weighted per Price Range / Change, 7.1257_4_22 ,Combined; Weight Adj Trade Metric, (0.3101), (0.674194)M Market Cap; for (0.000166) off adjusted level price of .000641;
Estimate of Forward Volume:
Shares Traded 5.48 DAYS: (319.121)M Min Volume Increase1: 0.2258 Min Volume Increase2: 0.2257 Min Volume Increase 3: 0.2252 Estimated Minimum Volume Shares to Trade LocallyM: (236) Estimated Factor NOT LOCAL in $$M: 1.722 Estimated Maximum Volume Shares to Trade LocallyM: (405.794) Estimated NOT LOCAL Price / Min Market Cap Price: 0.0004752212 (9.99_321%), Estimate of FWD Shares Traded per O/S Shares; 1.35_7_22, Weighted Avg Price to Min Market Cap Price;
About UNDT: Universal Detection Technology (seekingalpha.com/symbo...) is a developer of monitoring technologies, including chemical, biological, radiological, nuclear (seekingalpha.com/symbo...), and mold detection devices. The company on its own and with development partners is positioned to capitalize on opportunities related to Homeland Security. The Company is a reseller of Handheld Assays used for detection of Five Bioterrorism agents, Radiation Detection systems, and chemical agent detectors. For more information, please visit: www.udetection.com/.
[X];Own Shares; and Review the Company; Reporting Status is current;
Per Equity Last Report:May-11
Common Stock Amount:36.272M Paid In Equity:5.313M Accum Deficit(46.137M)
Equity:(4.552,310M)
3-Month Net Loss:(704,400K)
2004: $173.4 / Share;
Recent Monthly Share Volume: 2.326B Shares;
Trading Range for 5.48 MONTHS [Level]: .0003 to .0005; with a spike to .0026 on 786M Shares; 1 Year (78.07%);
Interesting Discussion: Share Equity is stated @ 14.140B;and why would another company assume the debt???
Adjusted Balance Sheet: AR 2,932 Inventory 728 PPE 14,754 FCC Licenses 20,409 Definite-lived intangible assets, net 1,878 AP -2,738 Current Debt -2,256 Long-term debt, financing and capital lease obligations -16,282
a.Total:19,425M
b.Top Line Gross Profit Annualized:16,668M
Therefore:That is not a bad turnover time period per A&B; 1.16_540 Years; and quite a premium to Reported Equity;
I do not own Shares of S, and this is not meant to comment on any fund or funds that may hold S in their portfolio; and not a comment of return year to date; either;
However;
Acquisition Range: 6.53 to 6.75 per Share; 19,536M to 20,196M; Which is very close to the FCC License Line Item Value of 20.4B; ***The difficulty for a company in the purchase, most likely will be obtaining a reconciliation of the FCC License(s) carrying value;
[If such a reconciliation exists];
S share price is fair @ present . 7x to .8x FCC Licenses; per recent Market Cap range;
Just a non-inflated opinion based on what I know about the company;
Sum Trading At: ,Primary Metric per CF: +$0.3 M, (90) ,Metric Weighted per Price Range / Change, 12.05_404 ,Combined Weight Adj Trade Metric, (196) ,for -($15)M Market Cap, for, (0.404705) off adjusted level price of .632205;
Estimate of Forward Activity:
Net $$MM Accumulated Deficit Since '97: (20.344) MinRetGrowth: 0.03 MinRetInv: 0.05 Weighted Cost of Capital: 94% Estimated Local Continuing Value in $$M: (6.857) Estimated Factor NOT LOCAL in $$M: 0.25 Estimated ContinuingValue: R&D Net Loss $$M: (1.713461) Est NOT LOCALPrice : 0.0475 (0.046), ,Factor Forward. (1.03336), ,Price To. (1.600M) , Net Loss / R&D Avg per '97 to Current;
Price weighted over 122 DAYS.....
Company Profile: iTech Medical: The research and commercial development of healthcare information systems and technologies. To date, the Company has focused on developing a proprietary platform called Muscle Pattern Recognition (MPR), a unique clinical and rehabilitation tool for the analysis of muscle function. iTech Medical is ISO 13485:2003 certified for the production and sale of surface electromyography (SEMG) diagnostic devices for clinical use.
Ambient Corp. (ABTG.OB) Announces Record Revenue for 2010 [View instapost]
ABTG: Recent Quarter 12M in Sales;
Per Equity @ Quarter End Mar-11; @ 6.75 Cents or Desired Market Cap Adjustment of (40M); Also Adjusted cash Balance by (7M); Which would leave a cash Balance of 1.729M;
Per Share Equity , Equity: $1M, Sum Trading At: ,Primary Metric(s) per Statement: (505.712) ,Metric Weighted per Price Range / Change, 6.78_404 ,Combined; Weight Adj Trade Metric, (480.97), for(40)M Market Cap; for (0.0241) off adjusted level price of .0916; Price Weighted to 5.00 DAYS w/ Year High of 15.3 Cents;
Estimate of Forward Activity:
Net$$MM Accum Deficit: (142.3) MinRetGrowth: 0.03 MinRetInv: 0.05 Weighted Cost of Capital: 104.43% Estimated Local Continuing Value in $$M: (47) Estimated Factor NOT LOCAL in $$M: (0.25_9_12_746) Estimated ContinuingValue: Maintain Min. Quarterly Sales$$MM: 12.2015 Estimated NOT LOCAL Price : 0.0885 0.03, Factor Forward.(Annualized). 2.99, Not Local Price To,(Annualized). 12M , Quarterly Sales Last Reported.
Profile: Ambient designs, develops and markets Ambient Smart Grid® communications technologies and equipment. Using open standards-based technologies along with in-depth industry experience, Ambient provides utilities with solutions for creating smart grid communication platforms and technologies.
ERF Wireless (ERFW) Improves Balance Sheet and Operations in Preparation of Further Expansion [View instapost]
messages.finance.yahoo...
See Yahoo Finance Message Post.
Reach Messaging Holdings, Inc. (RCMH.OB) Goes Public on OTCBB [View instapost]
Reach Messaging Holdings Inc. helps companies extend their brands through customized mobile applications and Bots used on instant messaging (IM) platforms. Since 2007, Reach Messaging has been in the Bot development business for America Online (seekingalpha.com/symbo...), which operates on the AOL Instant Messenger (seekingalpha.com/symbo...). The Company is transitioning to the mobile applications market and is currently developing a variety of apps for social media platforms including Facebook and all of the major mobile devices such as the iPhone, BlackBerry, Android and Digital Signage.
For more information, please visit www.reachmessaging.com
A leading developer of industry specific mobile phone application and specialized platform technology, today announced the Company will be launching a Physical Fitness App through which "CrossFit" athletes can communicate, challenge and compete with one another. The app will be available on the iPhone and Droid upon release, which the Company anticipates in the near future.
The mobile app itself will be a comprehensive tool designed specifically for the CrossFit athlete and include all the necessary tools for CrossFit such as a timer, list of CrossFit specific exercises to reference, Workout of the Day (seekingalpha.com/symbo...) tracker, and the ability to locate the nearest CrossFit Affiliate Gym. Additionally, the app will have a unique feature that allows CrossFit athletes all over the world to challenge other users, friends or random opponents to a specific workout. The user being challenged will be notified through push notification.
Reach Messaging Signs Deal With Mall Development Company to Use Its "Mall Buddy 2.0" Mobile App Throughout 12 Retail Mall Locations
Company's First Multi-Mall Deal is With the Largest Privately Owned Shopping Center Development and Management Company in the US.
Reach Messaging's "Mall Buddy 2.0" Platform is a free mobile app that consumers can download and use when shopping at participating retail malls. The app includes features such as "Reward Zone" gift card integration as well as other coupons and specials offered by stores in and around the mall, friend finder to locate other users in the area, one touch access to mall security and directions the mall. As outlined in the agreement, Reach Messaging will get a percentage of revenue generated by advertising sales to retail stores in and around the malls.
Per Equity @ .00478 / Share; Current Market Cap 4M; [Paid In Equity 4.835M], 840M Shares O/S.
Sum Trading At: ,Primary Metric per Equity: ($0.244208) M, 406.3 ,Metric Weighted per Price Range / Change, 6.301_404 ,Combined Weight Adj Trade Metric, 593.740 ,for -($1.044)M Market Cap, for, (0.001244) off adjusted level price of .006024;
Estimate of Forward Activity:
Equity $$MM: (0.244208)
MinRetGrowth: 0.03
MinRetInv: 0.05
Weighted Cost of Capital: 78.5%
Estimated Local Continuing Value in $$M: (0.132502)
Estimated Factor NOT LOCAL in $$M: 9.412007
Estimated ContinuingValue :In Line With Avg Oper Loss Annualized MRQ $M: '10 & '11: (1.247,113)
Est NOT LOCAL Price / 1.07M Market Cap : 0.001274_24_22
(0.0015), ,Factor Forward.
(0.858), ,Not Local Price To.
Quote: Enter RCMH and Get Info @
otcbb.com/asp/Info_Cen...
Profile:
www.reachmessaging.com
2010:85 Cents;
Volume YTD:66.119M Shares;
Do not own Shares; New Today; It appears to be an interesting speculative tech company; Review Company;
Noted:
1.0 HUF = 0.005_0222_38_43_09_9 AUD
1 AUD = 198.75 HUF
NewCardio (NWCI) Chosen to Provide QTinno Technology by Major Pharmaceutical Company [View instapost]
Which gave it a 8 Cent boost; from 25 Cents;[2.599M Market Cap]
Per Equity @ 32 Cents; Recent Quarterly Report;
Report Category, ,Notes, Report, Price, , Metric, , Weight, , Primary Weight Adj Trading Metric, ,Year / Desig/ DAY Weight Adj Price.
20. Deficit, (45) ,M, 10-Q 0.32 , (0.23) , 0.9063 , (0.21) ,July 2011, 0.29
21. Paid In Equity, 40 ,M, 10-Q 0.32 , 0.26 , 0.7813 , 0.20 ,July 2011, 0.25
22. Preferred, 0.000015 ,M, 10-Q 0.32 , 693019 , 1.015 , 703,629 ,July 2011, 0.32
23. Common Stk Amt, 0.0308 ,M, 10-Q 0.32 , 337 , 1.000 , 337 ,July 2011, 0.32
24. Other Inc or Loss 0.00 ,M, 10-Q 0.32 , 0.00 , 1.0313 , 0 ,July 2011, 0.33
Sum Trading At: ,Primary Metric per Equity: ($4.428) M, 693,356 ,Metric Weighted per Price Range / Change, 4.73_404 ,Combined Weight Adj Trade Metric, 703,966.1_15_8_86_404 ,for +$0.553M Market Cap, for, 0.017 on adjusted level price of .303;
Estimate of Forward Activity:
Equity $$MM: (4.428)
MinRetGrowth: 0.03
MinRetInv: 0.05
Weighted Cost of Capital: 92.47%
Estimated Local Continuing Value in $$M: (1.992072)
Estimated Factor NOT LOCAL in $$M: 4.824,522M
Estimated ContinuingValue :In Line With R&D Expense Annualized MRQ / Net Loss ttm$$M: (9.610,792)
Est NOT LOCAL Price / 5.24M Market Cap : 0.16_12_22
(0.2959) ,Factor Forward.
(0.54494) ,Not Local Price To.
Current Market Cap 10.72M; Off the high of $1.15_66_19
News / Recent Presentation's.
NewCardio Selected to Present at Wells Fargo Securities Healthcare Conference.
NewCardio Selected to Present at 33rd Annual International Conference of the IEEE Engineering in Medicine and Biology Society.
NewCardio Selected to present @ the Cardiac Diagnostic Technology at MDB Capital's Bright Lights Conference in New York City.
NewCardio Selected to Present Latest QTinno Performance Improvements at FDA-Sponsored Conference on Cardiovascular Safety in Drug Development.
About NewCardio, Inc.
NewCardio is a cardiac diagnostic and services company developing and marketing proprietary software platform technologies to provide higher accuracy to, and increase the value of, the standard 12-Lead 3D ECG.
NewCardio's 3D ECG technology software platform reduces the time and expense involved in assessing cardiac status while increasing the ability to diagnose clinically significant conditions which were previously difficult to detect.
NewCardio's software products and services significantly improve the diagnosis and monitoring of cardiovascular disease, as well as cardiac safety assessment of drugs under development.
For more information, visit newcardio.com.
Quote:Enter NWCI and Get Info @:
otcbb.com/asp/Info_Cen...
2008:4.32 / Share;
Do not own Shares of NWCI, Review the Company; Looking for 16.22 Cents with Volume; Volume YTD: 5M Shares;
Suspect Detection Systems Inc. (SDSS.OB) is “One to Watch” [View instapost]
Co. Statement:
- Total revenues during the past two years have exceeded $4M; During the quarter, the company completed a major sale to a governmental agency, and it is believed that follow-up sales with the customer are likely in the future.
In addition, the company has begun raising capital, which is intended to enable the company to grow significantly as it builds toward the fulfillment of its full business plan. The capital raise is expected to be completed in the coming months.
Per Equity @ 8.75 Cents; [Off the high of 11.2 Cents;],
Gross Profit as % of Revenue MRQ 90%;
Current Market Cap 6.507M;
2009:27 Cents;
Sum Trading At: ,Primary Metric per Equity: $1.357 M, 892 ,Metric Weighted per Price Range / Change, 4.63_4_38 ,Combined Weight Adj Trade Metric, 767.007 ,for +$0.5M Market Cap, for, 0.006398 on .081102 / Share;
Estimate of Forward Activity:
Equity $$MM: 1.357
MinRetGrowth: 0.03
MinRetInv: 0.05
Weighted Cost of Capital: 139.622%
Estimated Local Continuing Value in $$M: 0.399722M
Estimated Factor NOT LOCAL in $$M: 16.212047M
Estimated ContinuingValue :In Line With Sales Annualized 2011, MRQ: 6.480339M
Est NOT LOCAL Price / 4.43M Market Cap : 0.0578
0.085 ,Factor Forward.
0.68_3 ,Not Local Price To.
Quote:Enter SDSS and Get Info @
otcbb.com/asp/Info_Cen...
Profile:
finance.yahoo.com/q/pr...
Suspect Detection Systems Inc., through its subsidiary Suspect Detection Systems Ltd., is a developer of proprietary counter terrorism and crime prevention technology designed to identify threats in real-time, and prevent incidents before they are carried out.
The technology platform detects the hidden "hostile intent" of assailants - before they commit their intended acts - with a high degree of accuracy.
The system can also be used after a crime is committed to quickly identify criminals from among a general population pool, including suspects.
Learn more about Suspect Detection Systems and Cogito Technology at
www.sdss-corp.com.
Volume YTD: 5M Shares;
Do not own Shares of SDSS; Review Company; New Today;
Vicor Technologies (OTCBB: VCRT) - Breaking down the "PD2i(R) Studies" [View instapost]
Current Market Cap; 7.06M;
@ 10 Cents; Per Equity; Accum Deficit (59.708M); Equity (8.428M);
Development Stage Since 2000;
Desired Level / Sum Trading At: ,Primary Metric per Equity: ($8.428) M, 1000.013 ,Metric Weighted per Price Range / Change, 6.8_12_404 ,Combined Weight Adj Trade Metric, 1512.106 ,for -($1.7)M Market Cap, for, (0.04) off .14;
Estimate of Forward Activity:
Equity Deficit$$MM: (8)
MinRetGrowth: 0.03
MinRetInv: 0.05
Weighted Cost of Capital: 85.904%
Estimated Local Continuing Value in $$M: (4)
Estimated Factor NOT LOCAL in $$M: 1.33
Estimated ContinuingValue : In Line with Development Stage Expenses Since 2000;: (5.436,551)
Est NOT LOCAL Price / 4.048M Market Cap : 0.08606
(0.12) ,Factor Forward.
(0.74) ,Not Local Price To.
Profile:
Vicor is a medical diagnostics company focused on commercializing noninvasive diagnostic technology products based on its patented, proprietary point correlation dimension algorithm (the PD2i® Algorithm”).
The PD2i®Algorithm facilitates the ability of physicians to accurately risk stratify a specific target population to predict future pathological events such as autonomic nervous system dysfunction, cardiac mortality (either from arrhythmic death or congestive heart failure) and imminent death from trauma.
The Company believes that the PD2i® Algorithm represents a noninvasive monitoring technology that physicians and other members of the medical community can use as a new and accurate vital sign and is currently commercializing two proprietary diagnostic medical products which employ software utilizing the PD2i® Algorithm: the PD2i Analyzertm (sometimes also referred to as the PD2i Cardiac Analyzertm and the PD2i-VStm (Vital Sign). It is also anticipated that the PD2i®Algorithm applications will allow for the early detection of cerebral disorders as well as other disorders and diseases.
Quote:
Enter VCRT and Get Info @
otcbb.com/asp/Info_Cen...
Off the high of 75 Cents;
Do not own Shares of VCRT; Review the Company;
VPRO,Viropro,DSTI,Day Star Technologies,CTIC,Cell Therapeutics [View instapost]
Announcing Name Change @ Next Meeting of Shareholders;
Development Stage Since July-2003; however has not reported financials since May-10;
Per Last Equity Reported (459,299K) and with the addition of the following criteria;
Report a PROForma Fwd Net Loss of (1.763_656M); Per Next Report; [In line with Development Stage Expenses, Since ‘03]
What would the company look like??? @ .06 or 6 Cents;;
Report Category, ,Notes, Report, Price, , Metric, , Weight, , Primary Weight Adj Trading Metric, ,Year / Desig/ DAY Weight Adj Price.
20. Deficit, (16.08) ,M, 10-Q 0.06 , (0.63) , 0.9 , (0.57548) , July 2011, 0.06
21. Paid In Equity, 15.6 ,M, 10-Q 0.06 , 0.6472 , 0.8 , 0.5393 , July 2011, 0.05
22. Preferred, 0 ,M, 10-Q 0.06 , 0 , 1.0 , 0 , July 2011, 0.06
23. Common / Other, 0.0224 ,M, 10-Q 0.06 , 452 , 0.9 , 403 , July 2011, 0.05
24. Report a Fwd Net Loss (1.763_656) ,M, 10-Q 0.06 , (5.724664) , 0.9 , (5.343) , July 2011, 0.06
Sum Trading At: ,Primary Metric per Adjusted Equity: ($2.222,756) M, 445.86 ,Metric Weighted per Price Range / Change, 4.56 ,Combined Weight Adj Trade Metric, 397.404 ,for +$0.9M Market Cap, for, 0.005 on .055;
Description of Company;
Viropro Inc., a public company, offers Contractual Research and Manufacturing Services to the biopharmaceutical industry through cell line and process development.
The Manufacturing Processes Developed Are Out-licensed to various international partners who produce and distribute the final product. The company is currently seeking partnerships for its biosimilar (aka follow-on biologics) cell lines and manufacturing processes.
Viropro uses patented cell lines and expression vectors that clearly out-perform the industry standards and allow partnering companies to obtain industrially competitive yields. Our technology is ideally suited for Monoclonal Antibody process development.
Viropro, Inc. conducts operations through its subsidiaries Viropro International Inc., Biologics Process Development, Inc. and Alpha Biologics Sdn. Bhd.
Viropro specializes in the transfer of its technologies for industrial production of biopharmaceutical therapeutic proteins for the treatment of various diseases including cancer, diabetes, hepatitis and multiple sclerosis.
The Company’s principal objective is to provide its high-yield manufacturing process technology to biopharmaceutical companies in global markets with unmet medical and/or market needs.
Website:
(viropro.com);
BPD, located in Poway, CA, has been providing contract laboratory services to the biotechnology and biopharmaceutical industries for more than decade. The range of services includes molecular biology, cell culture, fermentation, protein purification, frozen storage, contract manufacturing, process scale-up and consulting services. BPD has an impressive list of clients that range from university laboratories to well-known biotechnology and biopharmaceutical companies.
Website:
(biologicspd.com)
Intas Biopharmaceuticals Limited is a fully integrated biopharmaceutical company based out of Ahmedabad, Gujarat, India. Since launch of biotechnology operations in May 2000, Research & Development (R&D) and Manufacturing of Biopharmaceutical products with a special focus on Oncology (Cancer) are the major thrust areas for the company. Intas Biopharmaceuticals is India's first and only biopharmaceutical company to receive European Union -Good Manufacturing Practice (EU-GMP) certification for its manufacturing facility.
Website:
(intasbiopharma.co.in)
Quote Enter VPRO and Get Info @
otcbb.com/asp/Info_Cen...
Profile:
finance.yahoo.com/q/pr...
2006: 1.50 / Share;
Recently off the low of .0023, and the high of 14 Cents;
[X] Own Shares and Review the Company;
11 Advertising Stocks That You Might Be Tempted to Buy [View article]
messages.finance.yahoo...
See Post on Yahoo Finance Message Board;
American Medical Alert Corp. Q4 2007 Earnings Call Transcript [View article]
MDHI, Medical Alarm Concepts, is similar to AMAC, Mentioned Above;
There was no specific mention of MDHI on seekingalpha.com; and this is an outdated posting; Adequate area to post information on MDHI.....
Similar Companies;
MDHI has some active interest in the company; There has been 3 Schedule 13D's filed recently; [General statement of acquisition of beneficial ownership];
Also, Filed to Report 10-Q Late; Company may be in the process of being purchased..... Finalizing Equity Schedules; etc;
Current Market Cap 475.3K; Last .0015 / Share;
Per Most Recent Quarterly Report, Per Equity @ .001275_404 / Share; 316.863M Shares O/S; Market Cap of 404K;
Sum Trading At: ,Primary Metric per Equity: ($2.049) M, 0.022504 ,Metric Weighted per Price Range / Change, 6.4_78_404 ,Combined Weight Adj Trade Metric, 0.03000375 ,for -($0.119_46)M Market Cap, for, (0.00038) off .00165;
Estimate of Forward Activity:
Equity Deficit$$MM: (2.049)
MinRetGrowth: 0.03
MinRetInv: 0.05
Weighted Cost of Capital: 71.4%
Estimated Local Continuing Value in $$M: (1.204_702)
Estimated Factor NOT LOCAL in $$M: 1.000102
Estimated ContinuingValue : In Line with 6 Mos Loss Annualized: (1.204_823)
Est NOT LOCAL Price : 0.0098
(0.004), ,Factor Forward.
(2.58_16_6) ,Price To.
Quote:Enter MDHI & Get Info @
otcbb.com/asp/Info_Cen...
Profile:
Medical Alarm Concepts™ currently offers a unique, patented medical emergency alarm system that is different from other personal emergency response (PERS) systems on the market today.
MDHI's MediPendant™ product provides several revolutionary and highly desirable features, including the ability to speak and listen to the operator directly through the pendant, an extended range of up to approximately 600+ feet from the base station enabling the user to move virtually anywhere in or around their home, and a call center staffed around the clock with all EMT-certified operators, who are guaranteed to stay on the line with the MediPendant™ user until the problem is resolved or help arrives. MediPendant's™ advanced technology also allows for three-way calling between the operator, the user and the dispatched first responders and/or a friend and family member.
They have also recently acquired two US Patents;
Both patents relate to existing and future technologies in the design and functionality of the medical alarm, a market that is growing at unprecedented rates. The re-issuance of these patents is a significant step toward ensuring the long-term success of the Company with regards to both its existing line of products as well as new products that are currently in design and/or development.
Link to Profile:
finance.yahoo.com/q/pr...
Website:
www.medicalalarmconcep.../
2009-Early 2010 $2.58 / Share;
July-10,_ .0098 after a Selloff from 25 Cents on 21M Share Volume;
YTD Volume Approaching 100M Shares;
Disclosure: [X] Own Shares; and Review the Company;
May acquire additional Shares;
RxNews Recap for Tuesday 12-22-09 [View instapost]
CTD Holdings, Inc. Manufacturing and marketing of Cyclodextrin-based compounds.
per Equity @ .063 / Share;
Sum Trading At: ,Primary Metric per Equity: $1.393 M, 630 ,Metric Weighted per Price Range / Change, 6.20 ,Combined Weight Adj Trade Metric, 903.622_404 ,for -($0.5)M Market Cap, for, (0.015) off .078
Estimate of Forward Activity:
Accum Deficit$$MM: (2.323)
MinRetGrowth: 0.032
MinRetInv: 0.059
Weighted Cost of Capital: 158.813%
Estimated Local Continuing Value in $$M: (0.7)
Estimated Factor NOT LOCAL in $$M: 0.0174
Estimated ContinuingValue : Operating Loss / In Line With Recent Reports: (0.0119)
Est NOT LOCAL Price : 0.06
(0.00033_4_13_8), ,Factor Forward.
2.3346, ,Not Local Price To Sales. Avg Sales 910,233K, and Increasing;
Quote:Enter CTDH and Get Info:
otcbb.com/asp/Info_Cen...
Profile:
finance.yahoo.com/q/pr...
Do not own Shares; Review the Company; Interested in Company and Sector;
Current Market Cap:3.2M; Price to Sales 3.5x;
2003:_.75 / Share;
Telecommunications Systems: Calling Another 'Stunningly Cheap' Stock [View article]
The balance sheet reports 216M of Equity; However if you deduct Cash, Goodwill, Deferred Tax Assets, add back Deferred Revenue, Non Current Deferred Tax Liab;
(7M);
Unbilled Receivables of 32M; which could be the government sector business that creates the revenue timing problem mentioned above;
Sales have increased considerably from 220M to 388M, '08, '09, '10;
R&D Exp from 16M to 30M; [Good to see that]
Stock based comp expense from 4M to 10M;[Good to See that as well]
So therefore; Mr Tos and his Anti-takeover provisions do not mean much when you are sitting on 80M in Cash; with the possibility of being paid an additional 300M; and whatever you received in other payments over the years;
[Note: Paid in Equity is 297.5M on Accum Deficit of 82.6M]
Estimate of Buyout Valuation:
Recent Net Income $$MM: 16
MinRetGrowth: 0.03
MinRetInv: 0.05
Weighted Cost of Capital: 360.722%
Estimated Local Continuing Value in $$M: 1.365 / 1.4M
Estimated Factor NOT LOCAL in $$M: 100.722
Estimated ContinuingValue: Gross Profit $$M: 138
Est NOT LOCAL Buyout Price : 5.33 / Share.
Estimated Buyout Valuation: $302.26M - $304.64
2.43, ,Factor Forward / Gross Profit per Shares;
2.20, ,Price To per Buyout Price;
1.1104x / 1.12x to Current Market Cap;
Net Cash provided by operating activities has increased from 26M to 73.4M;
Disclosure:
[X] Own Shares of TSYS. This is a comment / valuation estimate of a potential buyout based on recent 10-K Equity and Sales Disclosure;
This is not meant to comment on a specific fund or funds that may own shares of TSYS in their portfolio;
This is not meant to comment on Return Year To Date;
[Gross Profit YE 2010: Approx 140M]
Profile:
finance.yahoo.com/q/pr...
Website:
www.telecomsys.com////
Quote: Enter TSYS & Get Info @
otcbb.com/asp/Info_Cen...
2009:9.00 / Share;
Super Clean Hedge Fund with 56.710M Shares O/S;
I think Mr. TOS has done a great job in regards to that.....
Micro Identification Technologies, Inc. (MMTC.OB) – Bacteria Wars [View instapost]
Report Category, ,Notes, Report, Price, , Metric, , Weight, , Primary Weight Adj Trading Metric, ,Year / Desig, Weight Adj Price.
20. Accum Earnings or Deficit -37M, 10-Q, 0.0475 , (0.46) , 0.21 , (0.10) , Price1, 0.01
21.Preferred Stock 500K, 10-Q, 0.0475 , 34 , 0.42 , 14 ,Price2, 0.02
22. Paid in Equity 34M, 10-Q, 0.0475 , 0.49 , 0.84 , 0.41 ,Price3, 0.04
23. Other Equity ,[0M], 10-Q, 0.0475 , 0 , 1.60 , 0 ,Price4, 0.076
24. Common Stk Amt ,[35K], 10-Q, 0.0475 , 475 , 0.08 , 40 ,Price5, (0.004)
Sum Trading At: ,Primary Metric per SE: -($2.219) M, 508.605 ,Metric Weighted per Price Range / Change, 3 ,Combined Weight Adj Trade Metric, 54 ,for +$6.2M Market Cap, for, 0.0175 on adjusted level price of 3.00 Cents;
Estimate of Forward Activity:
Recent Net Loss $$MM: (0.428)
MinRetGrowth: 0.03
MinRetInv: 0.05
Weighted Cost of Capital: 92.528%
Estimated Local Continuing Value in $$M: (0.146328)
Estimated Factor NOT LOCAL in $$M: 3.07
Estimated ContinuingValue: R&D Net Loss $$M: (0.449228)
Est NOT LOCALPrice : 0.035
(0.001271), ,Factor Forward.
(28) ,Price To.
Profile:
finance.yahoo.com/q/pr...
Website:
www.nuvilex.com//
Quote:Enter NVLX & Get Info @:
otcbb.com/asp/Info_Cen...
Volume YTD:38M Shares;
Do not own Shares; New Today; Review Company;
[cNOTES on recent Analyst Upgrade]
Universal Detection Technology (UNDT) Signs Agreement with APP System Services for Radiation Detection Devices [View instapost]
Universal Detection Technology (seekingalpha.com/symbo...) Last Quote:$ 0.0005 , -0.0001, (-16.67%),
Volume 50.711M Shares; @ 3:58pm;
Per Shares Traded each DAY; last 5.48 DAYS;
@ Min Market Cap price of .0004752212; Market Cap of 1.929M per O/S Shares @ OTCBB.COM; [Current Market Cap 2.03M]
Report Category, ,Notes, Per Report, Price: , Metric. , Weight. , Combined Trading Metric ,Year / Designation, Weight Adj Price.
20.Volume Shares: (-49.3M) Volume :, 0.0004752212 , (0.0392) , 1.05 , (0.0412) ,Price1, 0.0005
21. Volume Shares: (-82.5M) Volume :, 0.0004752212 , (0.0234) , 1.23 , (0.0288) ,Price2, 0.0006
22.Volume Shares: (-28.8M) Volume :, 0.0004752212 , (0.0668) , 1.47 , (0.0984) ,Price3, 0.0007
23. Volume Shares: (-130.04M) Volume :, 0.0004752212 , (0.0148) , 1.64 , (0.0244) ,Price4, 0.0008
24. Volume Shares: (-26.9M) Volume :, 0.0004752212 , (0.0679) , 1.73 , (0.1174) , Price5, 0.0008
Desired Range:
Per Volume Last 5.48 DAYS, M of Shares: (319.121)M , (0.204636)M Market Cap; Sum Trading At: ,Primary Metric(s) per Volume: (0.21) ,Metric Weighted per Price Range / Change, 7.1257_4_22 ,Combined; Weight Adj Trade Metric, (0.3101), (0.674194)M Market Cap; for (0.000166) off adjusted level price of .000641;
Estimate of Forward Volume:
Shares Traded 5.48 DAYS: (319.121)M
Min Volume Increase1: 0.2258
Min Volume Increase2: 0.2257
Min Volume Increase 3: 0.2252
Estimated Minimum Volume Shares to Trade LocallyM: (236)
Estimated Factor NOT LOCAL in $$M: 1.722
Estimated Maximum Volume Shares to Trade LocallyM: (405.794)
Estimated NOT LOCAL Price / Min Market Cap Price: 0.0004752212
(9.99_321%), Estimate of FWD Shares Traded per O/S Shares;
1.35_7_22, Weighted Avg Price to Min Market Cap Price;
About UNDT:
Universal Detection Technology (seekingalpha.com/symbo...) is a developer of monitoring technologies, including chemical, biological, radiological, nuclear (seekingalpha.com/symbo...), and mold detection devices.
The company on its own and with development partners is positioned to capitalize on opportunities related to Homeland Security.
The Company is a reseller of Handheld Assays used for detection of Five Bioterrorism agents, Radiation Detection systems, and chemical agent detectors.
For more information, please visit:
www.udetection.com/.
[X];Own Shares; and Review the Company; Reporting Status is current;
Per Equity Last Report:May-11
Common Stock Amount:36.272M
Paid In Equity:5.313M
Accum Deficit(46.137M)
Equity:(4.552,310M)
3-Month Net Loss:(704,400K)
2004: $173.4 / Share;
Recent Monthly Share Volume: 2.326B Shares;
Trading Range for 5.48 MONTHS [Level]: .0003 to .0005; with a spike to .0026 on 786M Shares;
1 Year (78.07%);
For Quote Enter UNDT:Get Info @
otcbb.com/asp/Info_Cen...
We have volume!!! Hahaha!!!;
This type of quote / company volume is effective in many ways.....for many!!!
Why Verizon Must Buy Sprint [View article]
Interesting Discussion: Share Equity is stated @ 14.140B;and why would another company assume the debt???
Adjusted Balance Sheet:
AR 2,932
Inventory 728
PPE 14,754
FCC Licenses 20,409
Definite-lived intangible assets, net 1,878
AP -2,738
Current Debt -2,256
Long-term debt, financing and capital lease obligations
-16,282
a.Total:19,425M
b.Top Line Gross Profit Annualized:16,668M
Therefore:That is not a bad turnover time period per A&B; 1.16_540 Years; and quite a premium to Reported Equity;
I do not own Shares of S, and this is not meant to comment on any fund or funds that may hold S in their portfolio; and not a comment of return year to date; either;
However;
Acquisition Range: 6.53 to 6.75 per Share;
19,536M to 20,196M; Which is very close to the FCC License Line Item Value of 20.4B;
***The difficulty for a company in the purchase, most likely will be obtaining a reconciliation of the FCC License(s) carrying value;
[If such a reconciliation exists];
S share price is fair @ present . 7x to .8x FCC Licenses; per recent Market Cap range;
Just a non-inflated opinion based on what I know about the company;
TechFest Preview: Microsoft Researchers Show Off Live Translation and More [View article]
$ 0.25, -0.30, (-54.55%)
Per Cash Flow Cumulative from '97 to Last Quarterly Report; @ 22.75 Cents;
Report Category, ,Notes, Report, Price, , Metric, , Weight, , Primary Weight Adj Trading Metric, ,Year / Desig, Weight Adj Price.
20. Net Inc / Loss ,(-20M), 10-Q, 0.2275 , (0.42) , 4.62 , (1.92) , Price1, 1.05
21.Operating Cash ,[+2.03M], 10-Q, 0.2275 , 4 , 3.30 , 14 ,Price2, 0.75
22. Investing Cash ,[-88K], 10-Q, 0.2275 , (96) , 2.20 , (211) ,Price3, 0.50
23. Finance Cash ,[+6.643M], 10-Q, 0.2275 , 1.28 , 2.86 , 3.65 ,Price4, 0.65
24. Non Cash Adj ,[+12M], 10-Q, 0.2275 , 0.7 , (0.92) , (0.65) ,Price5, (0.21)
Sum Trading At: ,Primary Metric per CF: +$0.3 M, (90) ,Metric Weighted per Price Range / Change, 12.05_404 ,Combined Weight Adj Trade Metric, (196) ,for -($15)M Market Cap, for, (0.404705) off adjusted level price of .632205;
Estimate of Forward Activity:
Net $$MM Accumulated Deficit Since '97: (20.344)
MinRetGrowth: 0.03
MinRetInv: 0.05
Weighted Cost of Capital: 94%
Estimated Local Continuing Value in $$M: (6.857)
Estimated Factor NOT LOCAL in $$M: 0.25
Estimated ContinuingValue: R&D Net Loss $$M: (1.713461)
Est NOT LOCALPrice : 0.0475
(0.046), ,Factor Forward.
(1.03336), ,Price To.
(1.600M) , Net Loss / R&D Avg per '97 to Current;
Price weighted over 122 DAYS.....
Company Profile:
iTech Medical: The research and commercial development of healthcare information systems and technologies. To date, the Company has focused on developing a proprietary platform called Muscle Pattern Recognition (MPR), a unique clinical and rehabilitation tool for the analysis of muscle function.
iTech Medical is ISO 13485:2003 certified for the production and sale of surface electromyography (SEMG) diagnostic devices for clinical use.
Quote:
www.dailyfinance.com/q...
Profile:
finance.yahoo.com/q/pr...
YTD Volume: 553K
2008:$1.22; Early 2011:$1.05
Do not own Shares; Review the Company;
Ambient Corp. (ABTG.OB) Announces Record Revenue for 2010 [View instapost]
Per Equity @ Quarter End Mar-11; @ 6.75 Cents or Desired Market Cap Adjustment of (40M); Also Adjusted cash Balance by (7M); Which would leave a cash Balance of 1.729M;
Report Category, Per Report, Price: , Metric. , Weight. , Combined Trading Metric ,Year / Designation, Weight Adj Price.
20.Common Stock Amount: 1.6503M, Report 10-K :, 0.0675 , 68 , 2.27 , 153 ,Price1, 0.153
21. Treasury Stock 1M Shares: (200K), Report 10-K :, 0.0675 , (557) , 1.11 , (620) ,Price2, 0.08
22.Paid In Capital: 148.8MM, Report 10-K :, 0.0675 , 0.75 , 1.18 , 0.9 ,Price3, 0.08
23. Accum Deficit: (142.344M), Report 10-K :, 0.0675 , (0.78) , 1.33 , (1.04) ,Price4, 0.09
24. PROforma Adjustment:Cash (7.00M), Report 10-K :, 0.0675 , (16) , 0.9 , (14) , LowPrice, (0.06)
Per Share Equity , Equity: $1M, Sum Trading At: ,Primary Metric(s) per Statement: (505.712) ,Metric Weighted per Price Range / Change, 6.78_404 ,Combined; Weight Adj Trade Metric, (480.97), for(40)M Market Cap; for (0.0241) off adjusted level price of .0916;
Price Weighted to 5.00 DAYS w/ Year High of 15.3 Cents;
Estimate of Forward Activity:
Net$$MM Accum Deficit: (142.3)
MinRetGrowth: 0.03
MinRetInv: 0.05
Weighted Cost of Capital: 104.43%
Estimated Local Continuing Value in $$M: (47)
Estimated Factor NOT LOCAL in $$M: (0.25_9_12_746)
Estimated ContinuingValue: Maintain Min. Quarterly Sales$$MM: 12.2015
Estimated NOT LOCAL Price : 0.0885
0.03, Factor Forward.(Annualized).
2.99, Not Local Price To,(Annualized).
12M , Quarterly Sales Last Reported.
Quote;Market Cap 147.03M;
data.cnbc.com/quotes/A...
Profile:
Ambient designs, develops and markets Ambient Smart Grid® communications technologies and equipment. Using open standards-based technologies along with in-depth industry experience, Ambient provides utilities with solutions for creating smart grid communication platforms and technologies.
data.cnbc.com/quotes/A...
2000-2001; 75 Cents
Do not own Shares; Review the Company; Per Quarter Equity, Adjusted;